Quantum News
Sign InSign Up
Back to News
research

Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Relmada Therapeutics reported Q4 2025 financial results and business updates during its March 19, 2026 earnings call, highlighting progress in its clinical pipeline and operational milestones. CEO Sergio Traversa emphasized advancements in the company’s lead urology drug candidate, RE-104, with Phase 3 trial results expected by late 2026, targeting chronic pain conditions. CFO Maged Shenouda outlined a $50 million cash runway extending into 2027, supported by cost-cutting measures and strategic financing, despite a net loss of $32 million for 2025. Analysts questioned commercialization plans for RE-104, with management citing ongoing FDA discussions and potential partnerships to accelerate market entry post-approval. The call included forward-looking statements under SEC safe harbor provisions, noting risks tied to clinical trials, regulatory hurdles, and market competition.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (37).png
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159.06K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call March 19, 2026 4:30 PM EDT Company Participants Sergio Traversa - CEO & DirectorRaj Pruthi - Chief Medical Officer of UrologyMaged Shenouda - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLCUy Ear - Mizuho Securities USA LLC, Research DivisionFarzin Haque - Jefferies LLC, Research DivisionChristopher Liu - Lucid Capital Markets, LLC, Research DivisionKelsey Goodwin - Piper Sandler & Co., Research Division Presentation Operator Good afternoon, and welcome to the Relmada Therapeutics Fourth Quarter and Full Year 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for replay on the Relmada website. I would now like to turn the call over to Brian Ritchie from LifeSci Advisors. Please go ahead, Mr. Ritchie. Brian RitchieLifesci Advisors, LLC Good day, everyone, and thank you for joining us today. This afternoon, Relmada issued a press release providing a business update and outlining its financial results for the 3 months and year ended December 31, 2025. Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada's management team will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Relmada's press release issued today and the company's SEC filings, including in the annual report on Form 10-K for the year ended December 31, 2025, filed after the close today. This conference call also contains time-sensitive information that is accurate only as of the date of this live broadcast on

Read Original

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.